Illustration of Alexandria Real Estate Equities as a futuristic biotech REIT, showing modern lab campuses contrasted against falling stock charts and empty lab space, symbolizing the debate between deep-value opportunity and financial trap

🧬 Alexandria REIT (ARE): Deep Value Opportunity or Dangerous Lab Experiment?

Alexandria REIT (ARE) may be one of the market’s most fascinating contrarian plays. Founder Joel Marcus is aggressively buying shares while occupancy weakens, revenue shrinks, and Wall Street turns cautious. Here’s why this life-science REIT could either become a legendary recovery story… or a lab experiment gone wrong. 🧪🏢

Read entire article

Illustration of a stylized crown hovering above biotech molecules and financial charts, representing XOMA Royalty’s strategy of collecting biotech royalties without developing drugs.

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article